Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles - Additional Information (Detail)

v3.20.1
Acquisition of Patents and Intangibles - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 16, 2012
Feb. 29, 2020
Feb. 28, 2019
Feb. 29, 2020
Feb. 28, 2019
May 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible asset acquired gross   $ 3,500,000   $ 3,500,000    
Estimated aggregate future amortization expense in next twelve months   2,000,000   2,000,000    
Estimated aggregate future amortization expense in year two   2,000,000   2,000,000    
Estimated aggregate future amortization expense in year three   1,400,000   1,400,000    
Estimated aggregate future amortization expense in year four   1,100,000   1,100,000    
Estimated aggregate future amortization expense in year five   $ 940,000   $ 940,000    
Issuance of common stock shares   471,092,106   471,092,106   329,554,763
Common stock per shares   $ 0.001   $ 0.001   $ 0.001
ProstaGene, LLC            
Acquired Finite-Lived Intangible Assets [Line Items]            
Acquisition of ProstaGene LLC, value       $ 11,558,000    
Issuance of common stock shares   20,278,000   20,278,000    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Restricted common stock, shares   8,342,000   8,342,000    
Stock repurchase price, per share       $ 0.001    
ProstaGene, LLC | Investment Advisory, Management and Administrative Service            
Acquired Finite-Lived Intangible Assets [Line Items]            
Common stock per shares   $ 0.57   $ 0.57    
Investment earned shares   1,620,000   1,620,000    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Asset purchase, cash paid $ 3,500,000          
Estimated useful life of acquired asset       10 years    
Amortization expense related to acquired patents   $ 500,000 $ 500,000 $ 1,500,000 $ 700,000